In the manufacture of a GnRH agonist nonapeptide ethylamide, the protected D-leucine derivative is introduced at residue 6 through solution-phase fragment coupling rather than solid-phase elongation. Cbz-D-Leu-OH is dissolved in dichloromethane at 0–5 °C and activated with N,N′-diisopropylcarbodiimide and 1-hydroxybenzotriazole at a DIC/HOBt molar ratio of 1.00–1.05. The activated ester is filtered to remove diisopropylurea and added to a solution of Leu-Arg-Pro-ethylamide acetate in dimethylformamide. Coupling pH is maintained between 7.5–8.5 with N-methylmorpholine. Batch-to-batch moisture above 0.2% w/w in Cbz-D-Leu-OH reduces activated ester yield because water competes for the carbodiimide; the material is therefore pre-dried under vacuum at 25–30 °C for 4 h when ambient relative humidity exceeds 60%. Failure to control this parameter produces a persistent des-D-Leu deletion peptide that co-elutes with the target nonapeptide on C18 preparative HPLC and requires a second chromatography pass.

Industry compliance standards for this segment include ICH Q7 Chapter 7.3 for sampling and testing of incoming Cbz-D-Leu-OH, ICH Q11 for starting material justification when the D-Leu fragment is introduced at scale, USP 467 for residual solvents after lyophilization, and USP 621 for system suitability in the HPLC release method. The addition ratio of Cbz-D-Leu-OH to the C-terminal amine is 1.02–1.08 mol/mol at laboratory scale and 1.03–1.06 mol/mol at pilot scale, with the lower pilot range used when Karl Fischer moisture in the starting material is below 0.1% w/w and the higher range used for solvent-rich activated ester feeds. The downstream process after Cbz removal consists of mixed-anhydride coupling to the pyroglutamyl-tripeptide segment in tetrahydrofuran at -10 to -5 °C, followed by preparative reversed-phase C18 chromatography with 10 µm particles and 100 Å pore diameter. The terminal product is lyophilized leuprolide acetate API with chromatographic purity ≥99.0%, intended for sterile microsphere encapsulation or subcutaneous injection after aseptic formulation.

What Process Boundaries Govern Catalytic Hydrogenolysis of Cbz-D-Leu Fragments in Colistin Synthesis?

Because the Cbz group survives acidic aqueous workup but is removed selectively under transfer hydrogenolysis, Cbz-D-Leu-OH is coupled as the D-Leu6 residue to a side-chain-protected Dab5-containing segment in colistin synthesis. Unlike Fmoc chemistry, the Cbz group can be cleaved without interference when the Dab side chains are protected with tert-butoxycarbonyl or allyloxycarbonyl. The activation system is isobutyl chloroformate and N-methylmorpholine in tetrahydrofuran at -10 to -5 °C, generating a mixed anhydride that is added to the peptide segment in dimethylformamide at 0 °C over 30–45 min. The input ratio is 1.20–1.35 mol Cbz-D-Leu-OH per mol peptide amine because the sterically hindered α-amine of the Dab-rich segment consumes a portion of the activated ester through polar by-product formation; below 1.20 mol incomplete coupling yields an N-acetylated deletion impurity after final acetylation.

Industry compliance standards include the applicable Ph. Eur. colistimethate sodium monograph for the final lipopeptide, Ph. Eur. 2.2.29 for HPLC monitoring, ICH Q3D for residual palladium control ≤5 ppm after transfer hydrogenolysis, and ICH Q7 Chapter 8.1 for production operations when the fragment is manufactured in a multi-kilogram campaign. Cbz removal uses ammonium formate 4.0 mol per mol Cbz group with 5% Pd/C in tetrahydrofuran/water 1:1 at 25–30 °C until the N-benzyloxycarbonyl peak falls below 0.3 area % by HPLC. The transfer hydrogenolysis is run in a glass-lined reactor with a nitrogen purge; catalyst is charged as a 50% water-wet powder and removed through a 0.5 µm sintered stainless steel filter. Incomplete Cbz removal yields an N-benzyl carbamate-terminated peptide that elutes as a late-running impurity and inhibits the subsequent cyclization step. The terminal finished product is colistimethate sodium lyophilized powder or colistin sulfate API, obtained after cyclization, full deprotection, and lyophilization; both forms are used in sterile inhalation solutions and intravenous admixtures.

Following a protease-resistance screen in which an L-Leu residue at a metabolic labile site is replaced by D-Leu, a contract development and manufacturing organization may use Cbz-D-Leu-OH to prepare a short solution-phase fragment for a first toxicology lot. In this setting the material is converted to Cbz-D-Leu-N-hydroxysuccinimide ester with dicyclohexylcarbodiimide in ethyl acetate at 0–5 °C. The active ester is isolated by filtration, washed with cold water, and coupled to a partially protected peptide segment in dimethylformamide at 0–10 °C over 6–10 h. The addition ratio is 1.10–1.25 mol active ester per mol free amine because the N-hydroxysuccinimide ester undergoes first-order hydrolysis in the aqueous workup; ratios above 1.25 mol increase diketopiperazine formation at the following leucine junction and reduce yield. A documented limitation is that Cbz-D-Leu-OH is not suitable for Fmoc solid-phase chain elongation: the Cbz group is stable to piperidine deprotection and requires hydrogenolysis that cannot be performed on most synthesis resins without cleaving the peptide from the linker.

Industry compliance standards for this toxicology batch include ICH Q7 Chapter 7.3 for incoming material testing, ICH Q3C for residual ethyl acetate and dimethylformamide, and 21 CFR 312 for investigational clinical material when the lot is released for a Phase 1 study. The downstream process uses high-performance liquid chromatography on a C18 column with 5 µm particles and 120 Å pore diameter to isolate the D-Leu-substituted peptide from des-Leu and epimerization by-products. The residual free Cbz-D-Leu-OH content is monitored by chiral HPLC and controlled to ≤0.5% w/w in the isolated peptide. The terminal finished product type is a lyophilized peptide API batch of 0.5–5 kg solid, typically assigned to GLP toxicology or first-in-human formulation development.

Diastereomeric Purity Control for D-Leucine-Containing Peptide APIs

When a production batch of a D-Leu-containing peptide API is released, the manufacturer must demonstrate that the intended D-Leu residue has not epimerized to the corresponding L-Leu diastereomer during fragment coupling or final deprotection. Cbz-D-Leu-OH is used to prepare a defined D-Leu-containing diastereomer standard through a controlled solution-phase coupling route that mirrors the API assembly. For system suitability, the diastereomer standard is spiked into an API sample at 0.05–0.15% w/w; the standard stock is typically prepared as a 1.0 mg/mL solution in water/acetonitrile 50:50. Analytical separation uses a C18 column 150 × 4.6 mm, 5 µm particles, with mobile phase A consisting of 0.1% trifluoroacetic acid in water and mobile phase B consisting of 0.1% trifluoroacetic acid in acetonitrile; the gradient from 25% B to 55% B over 30 min at 1.0 mL/min is monitored at 220 nm. Resolution between the D-Leu peptide and the L-Leu diastereomer must be ≥2.0, and system precision across six injections must show relative standard deviation ≤2.0% according to USP 621.

Industry compliance standards governing this application include ICH Q6A decision tree #4 for chiral specificity, ICH Q3A for unspecified impurity thresholds, and Ph. Eur. 2.2.29 for liquid chromatography method transfer between laboratories. The downstream process for the standard includes preparative HPLC isolation, counterion exchange to acetate, and lyophilization in amber serum vials with controlled residual moisture. The terminal finished product type is a qualified impurity reference standard batch, issued with a certificate of analysis that lists diastereomeric purity, residual solvents, and chromatographic retention markers for use in batch release and stability studies.

When Cbz-D-Leucine Is Reduced to Cbz-D-Leucinol for Peptide Isostere Synthesis

Reduction of Cbz-D-Leu-OH to Cbz-D-leucinol is used to access chiral amino alcohol intermediates in hydroxyethylene and ketomethylene peptide isostere programs. In a glass-lined reactor, Cbz-D-Leu-OH is suspended in tetrahydrofuran and treated with sodium borohydride at 1.10–1.20 mol per mol amino acid, followed by slow addition of iodine at 0.50–0.55 mol per mol amino acid in tetrahydrofuran below 5 °C. The mixture is then maintained at 20–25 °C for 16 h; excess borohydride is quenched with methanol before aqueous sodium hydroxide hydrolysis. The Cbz group remains intact throughout the reduction, and the product is extracted into ethyl acetate, washed with brine, and concentrated to a low-moisture oil suitable for the next coupling step. Published data for this specific configuration at production scale is limited, so the reaction must be calorimetrically assessed before transfer to a 100 L or larger reactor.

Industry compliance standards include ISO 9001:2015 Clause 8.5.1 for control of production and service provision, REACH Regulation 1907/2006 Annex II for safety data sheet compositional disclosure, and ICH Q3C for residual tetrahydrofuran and methanol in the isolated Cbz-D-leucinol. In the subsequent isostere coupling, the addition ratio of Cbz-D-leucinol to the activated carboxyl component is 1.00–1.05 mol/mol, with the excess limited to prevent O-acylation side products that would otherwise contaminate the hydroxyethylene intermediate. The downstream process involves activation of a protected amino acid carboxylate with isobutyl chloroformate, coupling at -10 °C, and quenching with aqueous acid at 5 °C. The terminal finished product type is a chiral Cbz-protected amino alcohol intermediate, typically consumed in-house rather than isolated as a commercial peptide API.

In multi-site peptide API supply chains, N-benzyloxycarbonyl-D-leucine is released only after incoming identity testing, chiral purity verification, and residual solvent screening. The material is a white to off-white crystalline powder; a representative lot is sampled from 0.1% of containers for analysis. Chiral HPLC on a zwitterionic chiral stationary phase with 0.1% formic acid in methanol/water determines enantiomeric excess, with the L-leucine enantiomer limited to ≤0.5%. The industry compliance standards applicable to this release include ISO 9001:2015 Clause 8.5, ICH Q7 Chapter 7.3 for incoming production material sampling, and ICH Q3C for residual solvents such as ethyl acetate, tetrahydrofuran, and toluene. The addition ratio downstream is set at 1.03–1.08 mol Cbz-D-Leu-OH per mol peptide amine in solution-phase fragment coupling; this range accounts for activated ester hydrolysis during transfer and prevents unreacted amine from persisting into the next chain extension step. The downstream production process involves pre-drying the material under vacuum at 25–30 °C for 4 h when ambient relative humidity exceeds 60%, followed by dissolution in dimethylformamide and filtration through a 0.45 µm membrane to remove insoluble particulates. The terminal finished product type is a qualified protected amino acid starting material with a batch-specific certificate of analysis that supports peptide API synthesis under GMP conditions.